<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01158885</url>
  </required_header>
  <id_info>
    <org_study_id>T2009-002</org_study_id>
    <nct_id>NCT01158885</nct_id>
  </id_info>
  <brief_title>Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia</brief_title>
  <official_title>Clofarabine With Cytarabine for MRD Positive Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Therapeutic Advances in Childhood Leukemia Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Therapeutic Advances in Childhood Leukemia Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the ability of clofarabine + cytarabine to eliminate minimal residual
      disease (MRD) in acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL)
      patients whose bone marrows exhibit complete remission by morphology. The toxicity profile of
      this regimen will be evaluated in addition to toxicity experienced by patients who proceed to
      stem cell transplant. Overall length of remission will also be collected.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent studies have demonstrated that even low levels of minimum residual disease (MRD)
      (&gt;0.01% abnormal blasts) after aggressive re-induction therapy indicate a relatively poor
      outcome in relapsed acute lymphoblastic leukemia (ALL) patients, including those who proceed
      to allogeneic stem cell transplant (alloSCT). A similarly poor prognosis was seen in
      pediatric acute myelogenous leukemia patients with sub-morphologic disease prior to alloSCT.
      Studies to identify therapies that can eliminate persistent leukemia, have low toxicity
      profiles and can serve as a bridge to transplant are needed.

      This study will test the ability of clofarabine + cytarabine to eliminate minimal residual
      disease (MRD) in acute myelogenous leukemia and acute lymphoblastic leukemia patients whose
      bone marrows exhibit complete remission by morphology. The toxicity profile of this regimen
      will be evaluated in addition to toxicity experienced by patients who proceed to stem cell
      transplant. Overall length of remission will also be collected.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated for lack of accrual.
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">October 24, 2012</completion_date>
  <primary_completion_date type="Actual">October 24, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Minimal Residual Disease (MRD)</measure>
    <time_frame>Sample collected between Days 22-36 of courses 1 and 2</time_frame>
    <description>To be assessed in acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) patients whose bone marrows exhibit complete remission by morphology. Patient's bone marrow will be evaluated for the amount of minimal residual disease (MRD) present after treatment on courses 1 and 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of a Dose-Limiting Toxicity</measure>
    <time_frame>Beginning with the first dose of investigational product until 30 days following the last dose of clofarabine</time_frame>
    <description>All toxicities and adverse events will be collected from the first dose of study drug until 30 days following the last dose of Clofarabine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Toxicity During Hematopoietic Cell Transplant (HCT) for Patients Who Achieve Remission and Proceed to Transplant</measure>
    <time_frame>Every 3 months for life following completion of protocol therapy.</time_frame>
    <description>After the patient completes therapy on this protocol, data will continue to be collected regarding whether the patient proceeded to HCT. Toxicity and adverse event information will be collected.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Minimal Residual Disease</condition>
  <condition>Leukemia, Lymphoblastic, Acute</condition>
  <condition>Leukemia, Myelogenous, Acute</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A maximum of two courses of the following regimen will be administered.
Clofarabine: 20 mg/m2/day intravenously (IV) over 2 hours (given at hours 0 to 2) on days 1 through 5.
Cytarabine intravenous: 1 gram/m2/day intravenously (IV) over 2 hours to be given 4 hours after the initiation of clofarabine on days 1 through 5.
Methotrexate: to be given intrathecally (IT) to all acute lymphoblastic leukemia (ALL) patients on day 1 at the dose defined by age.
Intrathecal (IT) cytarabine: is optional for acute myelogenous leukemia (AML) patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>20 mg/m2/day intravenously (IV) over 2 hours (given at hours 0 to 2) on days 1 through 5.</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>Clolar</other_name>
    <other_name>CAFdA</other_name>
    <other_name>Cl-F-ara-A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine intravenous</intervention_name>
    <description>1 gram/m2/day intravenously (IV) over 2 hours to be given 4 hours after the initiation of clofarabine on days 1 through 5.</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>AraC</other_name>
    <other_name>Cytosine arabinoside</other_name>
    <other_name>Cytosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate to be given intrathecally (IT) to all acute lymphoblastic leukemia (ALL) patients on day 1 at the dose defined by age below:
8 mg for patients age 1-1.99
10 mg for patients age 2-2.99
12 mg for patients 3-8.99 years of age
15 mg for patients &gt;9 years of age</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>MTX</other_name>
    <other_name>Amethopterin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intrathecal (IT) Cytarabine</intervention_name>
    <description>Intrathecal (IT) cytarabine is optional for acute myelogenous leukemia (AML) patients.
If intrathecal cytarabine is to be given, it must be given at least 72 hours but not more than 7 days prior to the initiation of intravenous cytarabine.
Dose should be given according to age as defined below:
30 mg for patients age 1-1.99
50 mg for patients age 2-2.99
70 mg for patients &gt;3 years of age</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>AraC</other_name>
    <other_name>Cytosine arabinoside</other_name>
    <other_name>Cytosar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        A. INCLUSION CRITERIA

          1. Patients must be ≥1 and ≤ 21 years of age when enrolled onto this study.

          2. Diagnosis

               -  Patients must have a diagnosis of relapsed or refractory AML or ALL and,

               -  Patient must have an M1 marrow based upon a recovered marrow with less than 5%
                  blasts by conventional morphology and,

               -  Patient must have minimal residual disease (MRD) detected by either
                  multidimensional or conventional flow cytometry greater than 0.1% and less than
                  5% following any re-induction attempt and

               -  Patients must be CNS 1.

          3. Patient must have an ANC &gt;500/μL off cytokine support for at least 24 hours and
             platelets &gt;50,000 K/μL without platelet transfusion in the past seven days

          4. Performance Level Karnofsky &gt; 50% for patients &gt; 16 years of age and Lansky &gt; 50% for
             patients ≤16 years of age.

          5. Patient must have adequate venous access.

          6. Prior Therapy

               1. Patients must have fully recovered from the acute toxic effects of all prior
                  chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

               2. At least 21 days must have elapsed from prior chemotherapy, at least 7 days must
                  have elapsed since receiving biological therapy.

               3. It must be at least 45 days from any higher dose cytarabine therapy (&gt;1 gm/
                  m2/day).

               4. Patients on steroid taper must be on less than 0.5mg/kg/day with plans to
                  continue taper and discontinue the steroids.

          7. Renal and Hepatic Function Patient must have adequate renal and hepatic functions as
             indicated by the following laboratory values:

               1. Patients must have a normal calculated creatinine clearance as calculated below:

                    -  Pediatric Population (age &lt;18): Calculated creatinine clearance ≥ 90
                       ml/min/1.73m2 as calculated by the Schwartz formula for estimated glomerular
                       filtration rate (GFR) where GFR (ml/min/1.73 m2) = k*Height (cm)/serum
                       creatinine (mg/dl). k is a proportionality constant which varies with age
                       and is a function of urinary creatinine excretion per unit of body size;
                       0.45 up to 12 months of age; 0.55 children and adolescent girls; and 0.70
                       adolescent boys.

                    -  Adult Population (age ≥18): Serum creatinine ≤1.0 mg/dL; if serum creatinine
                       &gt;1.0 mg/dL, then the estimated glomerular filtration rate (GFR) must be &gt; 60
                       mL/min/1.73 m2 as calculated by the Modification of Diet in Renal Disease
                       equation where Predicted GFR (ml/min/1.73 m2) = 186 x (Serum
                       Creatinine)-1.154 x (age in years)-0.023 x (0.742 if patient is female) x
                       (1.212 if patient is black.

               2. Conjugated (direct) serum bilirubin ≤ 1.5 x ULN for age.

               3. Alanine transaminase (ALT) ≤ 2.5 × ULN for age.

               4. Alkaline phosphatase ≤ 2.5 × ULN for age.

               5. Serum amylase ≤ 1.5 ULN for age.

               6. Serum Lipase is ≤ ULN for age.

          8. Patient must have a shortening fraction &gt; 28% by echocardiogram or an ejection
             fraction &gt; 50% by MUGA

          9. Reproductive Function

               1. Female patients of childbearing potential must have a negative urine or serum
                  pregnancy test confirmed prior to enrollment.

               2. Female patients with infants must agree not to breastfeed their infants while on
                  this study.

               3. Male and female patients of child-bearing potential must agree to use an
                  effective method of contraception approved by the investigator during the study.

         10. Patient must agree to submission of blood and bone marrow for MPF assessment of MRD to
             TACL centralized lab.

        B. EXCLUSION CRITERIA

        Patients will be excluded if they meet any of the following criteria:

          1. Patients with previous HSCT within previous 180 days.

          2. Patients who have had prior treatment with clofarabine.

          3. Patients with CNS2 or CNS 3 disease or bulky chloromatous disease.

          4. Patients with Down Syndrome.

          5. Patients with a previous history of veno-occlusive disease (VOD) or findings
             consistent with a diagnosis of VOD, defined as: conjugated serum bilirubin &gt;1.4 mg/dL
             AND unexplained weight gain greater than 10% of baseline weight or ascites AND
             hepatomegaly or right upper quadrant pain without another explanation, OR reversal of
             portal vein flow on ultrasound, OR pathological confirmation of VOD on liver biopsy.

          6. Patients with a systemic fungal, bacterial, viral, or other infection not controlled
             (defined as exhibiting ongoing signs/symptoms related to the infection and without
             improvement, despite appropriate antibiotics or other treatment).

          7. Use of investigational agents within 30 days of planned treatment on this protocol.

          8. Patient is receiving or plans to receive concomitant chemotherapy, radiation therapy,
             immunotherapy or other anti-cancer therapy other than is specified in the protocol.

          9. Pregnant or lactating patients.

         10. Any significant concurrent disease, illness, psychiatric disorder or social issue that
             would compromise patient safety or compliance, interfere with consent, study
             participation, follow up, or interpretation of study results.

         11. Have had a diagnosis of another malignancy, unless the patient has been disease-free
             for at least 3 years following the completion of curative intent therapy with the
             following exceptions:

               1. Patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical
                  intraepithelial neoplasia, regardless of the disease-free duration, are eligible
                  for this study if definitive treatment for the condition has been completed.

               2. Patients with organ-confined prostate cancer with no evidence of recurrent or
                  progressive disease based on prostate-specific antigen (PSA) values are also
                  eligible for this study if hormonal therapy has been initiated or a radical
                  prostatectomy has been performed.

         12. Patient has active acute (greater than grade II) or active chronic extensive GVHD.
             Patients who are on a tapering dose of immunosuppressants will be permitted (tapering
             calcineurin inhibitor and/or less than 0.5 mg/kg/day of steroids).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Blythe Thomson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Seattle Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Carolina-Levine Children's Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>http://www.tacl.us</url>
    <description>Therapeutic Advances in Childhood Leukemia &amp; Lymphoma Consortium web site</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 30, 2010</study_first_submitted>
  <study_first_submitted_qc>July 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2010</study_first_posted>
  <results_first_submitted>October 3, 2018</results_first_submitted>
  <results_first_submitted_qc>September 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 7, 2019</results_first_posted>
  <last_update_submitted>September 13, 2019</last_update_submitted>
  <last_update_submitted_qc>September 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsed</keyword>
  <keyword>relapse</keyword>
  <keyword>refractory</keyword>
  <keyword>Minimal Residual disease</keyword>
  <keyword>MRD</keyword>
  <keyword>MRD positive</keyword>
  <keyword>MRD+</keyword>
  <keyword>ALL</keyword>
  <keyword>Acute lymphoblastic leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>Acute myelogenous leukemia</keyword>
  <keyword>Relapsed AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Arm</title>
          <description>Clofarabine, Cytarabine, Methotrexate
See detailed description in Interventions section.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Course 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Course 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Arm</title>
          <description>Clofarabine, Cytarabine, Methotrexate
See detailed description in Interventions section.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Minimal Residual Disease (MRD)</title>
        <description>To be assessed in acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) patients whose bone marrows exhibit complete remission by morphology. Patient's bone marrow will be evaluated for the amount of minimal residual disease (MRD) present after treatment on courses 1 and 2.</description>
        <time_frame>Sample collected between Days 22-36 of courses 1 and 2</time_frame>
        <population>Study was closed prematurely and none of the patients treated were eligible for analysis of disease response.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Clofarabine, Cytarabine, Methotrexate
See detailed description in Interventions section.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimal Residual Disease (MRD)</title>
          <description>To be assessed in acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) patients whose bone marrows exhibit complete remission by morphology. Patient's bone marrow will be evaluated for the amount of minimal residual disease (MRD) present after treatment on courses 1 and 2.</description>
          <population>Study was closed prematurely and none of the patients treated were eligible for analysis of disease response.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of a Dose-Limiting Toxicity</title>
        <description>All toxicities and adverse events will be collected from the first dose of study drug until 30 days following the last dose of Clofarabine</description>
        <time_frame>Beginning with the first dose of investigational product until 30 days following the last dose of clofarabine</time_frame>
        <population>All patients treated on Treatment Course 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Clofarabine, Cytarabine, Methotrexate
See detailed description in Interventions section.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of a Dose-Limiting Toxicity</title>
          <description>All toxicities and adverse events will be collected from the first dose of study drug until 30 days following the last dose of Clofarabine</description>
          <population>All patients treated on Treatment Course 1.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Toxicity During Hematopoietic Cell Transplant (HCT) for Patients Who Achieve Remission and Proceed to Transplant</title>
        <description>After the patient completes therapy on this protocol, data will continue to be collected regarding whether the patient proceeded to HCT. Toxicity and adverse event information will be collected.</description>
        <time_frame>Every 3 months for life following completion of protocol therapy.</time_frame>
        <population>None of the patients treated on Treatment Course 1 proceeded to HCT. 1 patient upon completion of Treatment Course 1 proceeded with Bone Marrow Transplant and 1 patient was removed early from protocol treatment during Course 1 due to progressive disease.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Clofarabine, Cytarabine, Methotrexate
See detailed description in Interventions section.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Toxicity During Hematopoietic Cell Transplant (HCT) for Patients Who Achieve Remission and Proceed to Transplant</title>
          <description>After the patient completes therapy on this protocol, data will continue to be collected regarding whether the patient proceeded to HCT. Toxicity and adverse event information will be collected.</description>
          <population>None of the patients treated on Treatment Course 1 proceeded to HCT. 1 patient upon completion of Treatment Course 1 proceeded with Bone Marrow Transplant and 1 patient was removed early from protocol treatment during Course 1 due to progressive disease.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 2 years</time_frame>
      <desc>The definition of AE and SAE used to collect adverse event information does not differ from the clinicaltrials.gov definitions.</desc>
      <group_list>
        <group group_id="E1">
          <title>Single Arm</title>
          <description>Clofarabine, Cytarabine, Methotrexate
See detailed description in Interventions section.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Grade 4 Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Leukopenia NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neutrophil count</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study only enrolled two patients and closed early due to low accrual.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Peggy Romano, BA, CCRP</name_or_title>
      <organization>Therapeutic Advances in Childhood Leukemia &amp; Lymphoma (TACL) / Children's Hospital Los Angeles</organization>
      <phone>323-361-5505</phone>
      <email>promano@chla.usc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

